Molecular Subtype
HER2-Positive Breast Carcinoma
CI-CAN-00007795Explore in graph →
140 active trials3 approved drugs93 evidence items
Loading cancer entity…
Molecular Subtype
CI-CAN-00007795Explore in graph →
Clinical trials
377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (52)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07787338 | SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer | not yet recruiting | Phase 2 | 80 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07726342 | SMP-656 for HER2-Positive Advanced Breast Cancer | not yet recruiting | Phase 2 | 60 | Chengdu SciMount Pharmatech Co., Ltd.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07716046 | Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer(FACET) | not yet recruiting | Phase 2 | 240 | Fudan UniversityOTHER | 0 | Jul 21, 2026 | clinicaltrials |
| NCT07217990 | Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer(NoCUT-BC) | not yet recruiting | Phase 1 / Phase 2 | 84 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07581795 | Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer(SPECTACLE) | not yet recruiting | Phase 2 | 140 | Fudan UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07417241 | SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study | not yet recruiting | Phase 2 | 100 | Peking University Cancer Hospital & InstituteOTHER | 0 | Feb 18, 2026 | clinicaltrials |
| NCT07366840 | RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure(BRIGHT) | not yet recruiting | Phase 2 / Phase 3 | 268 | Fudan UniversityOTHER | 0 | Jan 26, 2026 | clinicaltrials |
| NCT07178938 | Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain Metastases(THERANOVA) | not yet recruiting | Phase 2 | 10 | MedSIROTHER | 0 | Nov 14, 2025 | clinicaltrials |
| NCT07179939 | Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study | not yet recruiting | Phase 2 | 288 | Fudan UniversityOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07116824 | HB1801 Combined Treatment of HER2-positive Breast Cancer | not yet recruiting | Phase 2 | 80 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Aug 12, 2025 | clinicaltrials |
| NCT06973525 | This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.(HER2-DM-NACT) | not yet recruiting | Phase 2 | 30 | Hebei Medical University Fourth HospitalOTHER | 0 | Aug 5, 2025 | clinicaltrials |
| NCT07019337 | Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer | not yet recruiting | Phase 2 | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jun 13, 2025 | clinicaltrials |
| NCT06548178 | T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer | not yet recruiting | Phase 2 | 242 | Fudan UniversityOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT04158856 | Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer(SHERO) | not yet recruiting | Phase 2 | 60 | xuexin heOTHER | 0 | Nov 12, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Aug 26, 2026source: clinicaltrials